💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Influenza A Virus Hemagglutinin

CHEMBL6068377 Phase 4 ได้รับการอนุมัติ Vaccine component
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This vaccine component contains the hemagglutinin surface protein from influenza A virus strains, which the immune system learns to recognize and attack. Hemagglutinin is the primary target of protective antibodies generated by influenza vaccination.

ด้านการรักษา

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Stroke Lymphoma Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer

กลไกการออกฤทธิ์

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This vaccine component contains the hemagglutinin surface protein from influenza A virus strains, which the immune system learns to recognize and attack. Hemagglutinin is the primary target of protective antibodies generated by influenza vaccination.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Influenza A Virus Hemagglutinin is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068377. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.